Subcutaneus gammaglobulin in primary immunodeficiencies. Experience at the National Institute of Pediatrics and review of literature

Abstract

Primary immunodeficiencies (PID) were first described over 50 years ago. They are hereditary disorders, mostly monogenic diseases that produce immune system dysfunction. The most frequent PID group is primarily antibody deficiencies, where antibody production is im- paired, for which reason these patients require to use exogenous immunoglobulin for a long time in order to maintain homeostasis. Immunoglobulin products and routes of administration have changed over the years. Subcutaneous immunoglobulin administration is effective and offers some advantages over the intravenous route: severe adverse reactions are less frequent, medical care costs can be reduced and patients can administer it by themselves at home, improving their quality of life. Subcutaneous route has been used in twenty-one PID patients at our institution. In the near future, our goal is to establish a self-administered home program that will al- low to reduce costs for patients as well as for health systems. We report our experience using subcutaneous route for PID patients, and a literature review on this topic.

Keywords

• Inmunoglobulina
• gammaglobulina
• subcutánea
• inmunodeficiencias